Kennedy B J, Bloomfield C D, Kiang D T, Vosika G, Peterson B A, Theologides A
Cancer. 1978 Jan;41(1):23-8. doi: 10.1002/1097-0142(197801)41:1<23::aid-cncr2820410106>3.0.co;2-y.
Fifty-three patients with advanced lymphocytic lymphoma were randomly assigned to treatment with the combination cyclophosphamide, vincristine, and prednisone (CVP) or the same agents used successively in maximal doses (C-V-P). Complete remissions occurred in 68% with CVP and 48% with C-V-P. For patients with nodular lymphoma, the complete remission rate was 81% with CVP and 46% with C-V-P. In patients with diffuse lymphoma a complete remission rate of 50% was obtained with both regimens. The median duration of response was longer for patients who obtained complete remission with CVP (37+ months) than for those entering remission with C-V-P (25+ months). More patients treated with CVP still survive. Current results suggest that CVP is a better induction regime than C-V-P in patients with nodular lymphoma. However, in patients with diffuse lympoocytic lymphoma, neither regimen results in more than 50% complete remissions or significant numbers of prolonged responses. More effective therapy is needed.
53例晚期淋巴细胞性淋巴瘤患者被随机分配接受环磷酰胺、长春新碱和泼尼松联合治疗(CVP)或依次使用最大剂量的相同药物治疗(C-V-P)。CVP治疗的完全缓解率为68%,C-V-P治疗的完全缓解率为48%。对于结节性淋巴瘤患者,CVP治疗的完全缓解率为81%,C-V-P治疗的完全缓解率为46%。在弥漫性淋巴瘤患者中,两种治疗方案的完全缓解率均为50%。CVP治疗获得完全缓解的患者的中位缓解持续时间(37+个月)比C-V-P治疗进入缓解的患者更长(25+个月)。接受CVP治疗的患者存活人数更多。目前的结果表明,在结节性淋巴瘤患者中,CVP是比C-V-P更好的诱导治疗方案。然而,在弥漫性淋巴细胞性淋巴瘤患者中,两种治疗方案的完全缓解率均不超过50%,也没有大量的长期缓解。需要更有效的治疗方法。